Olivia C. Finney

Keppel Street
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications

Preparation of Cuvette-Based Sorters for Sorting Submicron Microbial Cells and Viruses from Environmental and Biological Samples.

Preparation of Cuvette-Based Sorters for Sorting Submicron Microbial Cells and Viruses from Environmental and Biological Samples.

Journal: Current protocols
Published: August 22, 2025

Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Publisher Correction: Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Journal: Nature medicine
Published: August 05, 2025

Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Distinct patient, tumour and chimeric antigen receptor T-cell characteristics are associated with initiating versus sustaining responses to idecabtagene vicleucel in relapsed and refractory multiple myeloma.

Journal: British journal of haematology
Published: December 09, 2024

Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study.

Journal: Cancer immunology research
Published: June 05, 2024

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial.

Journal: Nature medicine
Published: May 31, 2024

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.

Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial.

Journal: Nature medicine
Published: July 28, 2022

Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.

Chemoprophylaxis Vaccination: Phase I Study to Explore Stage-specific Immunity to Plasmodium falciparum in US Adults.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: June 25, 2019

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.

Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.

Journal: Blood
Published: May 06, 2019

CD19 CAR T cell product and disease attributes predict leukemia remission durability.

CD19 CAR T cell product and disease attributes predict leukemia remission durability.

Journal: The Journal of clinical investigation
Published: March 13, 2019

Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.

Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.

Journal: Annals of neurology
Published: January 19, 2019

Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.

Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.

Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: August 05, 2018

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates.

Journal: Cancer discovery
Published: December 05, 2017
Showing 1-12 of 22

Last Updated: 09/26/2026